Abstract: Objective 　To evaluate the clinical application of autologous dendritic tumor vaccination on brain glioma, and to access the alterations of T cell subpopulation in patient s with brain glioma before and after autologous immunotherapy. Methods 　The experimental group (21 Glioma patients) received vaccinations of autologous dendritic cell pulsed with autologous tumor peptides, while the cont rol group (19 glioma patient s) only received the regular treatment s. Following-ups were carried out and the T cell subpopulations were measured. Results 　The median survival time of the experimental group (29 months) was significantly longer than that of cont rol group (10 month) ( P < 0. 05) . The levels of CD3 ⁺ and CD4 ⁺ and the ratio of CD4 ⁺ / CD8⁺ ratio in peripheral blood in glioma patients were significantly lower compared with the healthy control, the levels of CD3 ⁺ CD4⁺ , CD8 ⁺ and the CD4 ⁺ CD8 ⁺ ratio were significantly increased after immunotherapy than before, but the CD4⁺ / CD8⁺ ratio remained lower compared with the healthy control. Conclusion 　The immune functions of glioma patients were suppressed.Immunotherapy could prolong the survival time of the glioma patient by reconst ructing and enhancing some parts of the tumor immunity.